Fig. 4From: Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from ChinaCA125 in patients with different BRCA status in the second-line maintenance group. Note: There were two patients with BRCA mutation, four patients with BRCA wild-type, one patient with BRCA suspected pathological mutation and also three patients with BRCA status unknown in this groupBack to article page